- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Gland Pharma Names Ajay Sahni President of French Subsidiary Phixen SAS

Hyderabad: Gland Pharma Limited has appointed Ajay Sahni as the President of Phixen SAS, a wholly owned step-down subsidiary of the company, with effect from November 30, 2026. He will replace Alain Kirchmeyer and report to the Chief Executive Officer of Gland Pharma Limited.
The appointment was made by the Supervisory Board of Directors of Phixen SAS, as communicated by Gland Pharma in a regulatory filing.
The appointment follows the company's earlier communication dated October 30, 2026, regarding Sahni's appointment as the Chief Executive Officer of Gland Pharma International Pte. Ltd., Singapore, where he is responsible for the Cenexi business. With his new role, he will also take charge as President of Phixen SAS from November 30.
Sahni has more than 36 years of experience in the FMCG and pharmaceutical industries, particularly in financial management, business development and general management. During his career, he has held several leadership positions, including Finance Director, Project Manager – Business Development, Director of Financial Control, Planning and Analysis, Regional Finance Director for South and South-East Asia, President and Managing Director.
He has worked with several companies, including Sanofi SA, Sanofi-Synthelabo Inc., Sanofi-Synthelabo Pte. Ltd., Ferring Pharmaceuticals and Wockhardt France SAS. His professional experience also includes roles in subsidiaries such as Laboratoires Negma SAS, Wockhardt Bio AG and Pinewood Healthcare Ltd.
In his previous leadership assignments, Sahni served as Managing Director of Pinewood Healthcare Ltd. in Ireland and Wockhardt Bio AG in Switzerland. He also served as President of Wockhardt France SAS and its subsidiaries. His professional experience spans France, Belgium, Ireland, Switzerland, Singapore and the United States.
Sahni holds a Bachelor's degree in Business Administration from the European University of Brussels, Belgium. The company stated in its regulatory filing that disclosure of relationships between directors was not applicable in connection with the appointment.
Gland Pharma has informed the stock exchanges that Sahni's appointment as President of Phixen SAS will take effect on November 30, 2026.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

